Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vibegron in pediatric neurogenic detrusor overactivity on clean intermittent catheterization
2021-000676-11Phase 2Active
- Sponsor
- Urovant Sciences
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vibegron in detrusor hyperreflexia (DH) and neurogenic bladder, sponsored by Urovant Sciences. Primary endpoint: Change from baseline in maximum cystometric capacity. Started Nov 2022; status: active.
02
Drugs
vibegron
03
Conditions
detrusor hyperreflexia (DH)neurogenic bladder
Beyond the preview
Go deeper on 2021-000676-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000676-11.